Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
2017 oncology nursing drug handbook / / Gail M. Wilkes, MS, APRN-BC, AOCN, oncology nursing consultant Kilauea, Hawaii, Margaret Barton-Burke PhD, RN, FAAN, director of Nursing Research Memorial Sloan Kettering Cancer Center New York, New York
| 2017 oncology nursing drug handbook / / Gail M. Wilkes, MS, APRN-BC, AOCN, oncology nursing consultant Kilauea, Hawaii, Margaret Barton-Burke PhD, RN, FAAN, director of Nursing Research Memorial Sloan Kettering Cancer Center New York, New York |
| Autore | Wilkes Gail M. |
| Pubbl/distr/stampa | Burlington, MA : , : Jones & Bartlett, , [2017] |
| Descrizione fisica | 1 online resource (3,329 pages) : illustrations |
| Disciplina | 616.994061 |
| Soggetto topico |
Cancer - Chemotherapy
Antineoplastic agents Cancer - Nursing |
| ISBN | 1-284-11719-7 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910162769603321 |
Wilkes Gail M.
|
||
| Burlington, MA : , : Jones & Bartlett, , [2017] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advances and Prospects of 3-D Metal-Based Anticancer Drug Candidates
| Advances and Prospects of 3-D Metal-Based Anticancer Drug Candidates |
| Autore | Arjmand Farukh |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Singapore : , : Springer, , 2024 |
| Descrizione fisica | 1 online resource (292 pages) |
| Disciplina | 616.994061 |
| Altri autori (Persone) |
TabassumSartaj
KhanHuzaifa Yasir |
| ISBN | 981-9701-46-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface -- Contents -- About the Authors -- Chapter 1: Introduction -- 1.1 Introduction -- 1.1.1 Overview of Metal-Based Chemotherapeutic Agents in Cancer Oncology -- References -- Chapter 2: Classification of Metal-Based Anticancer Chemotherapeutic Agents -- 2.1 Schiff Base Ligands -- 2.2 Nitrogen-Containing Heterocyclic Compounds -- 2.3 Natural Flavonoid Ligands -- 2.4 Amino Acid Ligands -- 2.5 β-Diketone Ligands -- 2.6 Semicarbazones -- 2.7 NSAID Ligands -- References -- Chapter 3: Interaction Studies of Metal-Based Anticancer Drug Entities with Potential Therapeutic Targets -- 3.1 Interaction Studies with the Potential Therapeutic Targets DNA, RNA, and Proteins -- 3.2 Different Binding Modes of Metal-Based Drugs: Covalent and Non-covalent Binding -- 3.2.1 Covalent Binding of Metal-Based Drugs to Biomolecules -- 3.2.1.1 Non-Covalent Modes -- 3.2.1.2 Electrostatic Interaction -- 3.2.1.3 Groove Binding -- 3.2.1.4 Intercalation -- 3.2.1.5 Threading Intercalation -- 3.2.1.6 Metalloinsertion -- References -- Chapter 4: Biophysical and Spectroscopic Techniques to Validate the Interaction with Therapeutic Targets -- 4.1 Primary Techniques -- 4.1.1 UV-Vis Absorption Spectroscopy -- 4.2 Emission Spectroscopy -- 4.2.1 Fluorometric Assays -- 4.2.2 Competitive Displacement Assay -- 4.2.3 Circular Dichroism Spectroscopy -- 4.2.4 Thermal Melting Point -- 4.2.5 NMR Studies -- 4.2.6 X-Ray Crystallography -- 4.2.7 Viscosity -- 4.2.8 Cyclic Voltammetry -- 4.3 Electrophoretic Techniques -- 4.3.1 Agarose Gel Electrophoresis of pBR322 DNA -- 4.3.1.1 Oxidative DNA Damage -- 4.3.1.2 Artificial Chemical Nuclease Activity -- 4.4 tRNA Cleavage -- References -- Chapter 5: DNA Condensation Processes Mediated by Metal-Based Drug Entities and Morphological Studies -- 5.1 Introduction.
5.1.1 Advantages of Inorganic Metal-Based Condensing Agents over Other DNA Condensing Agents -- 5.2 Morphology of DNA Condensates -- 5.2.1 Toroids -- 5.2.2 Non-Toroidal Shapes -- 5.3 Mechanisms of DNA Condensation Fostered by Metal Complexes -- 5.3.1 Electrostatic Interactions -- 5.3.2 Intercalation π-π Interactions -- 5.3.3 Covalent Binding -- 5.3.4 Hydrogen Bonding -- 5.4 Biological Applications of DNA Condensation Process -- 5.4.1 Antitumor Agents -- 5.4.2 Gene Delivery -- References -- Chapter 6: Molecular Docking and Computational In Silico Investigations of Metal-Based Drug Agents -- 6.1 Introduction -- 6.2 Molecular Docking -- 6.2.1 General Application of Molecular Docking -- 6.2.2 Molecular Docking Tools -- References -- Chapter 7: Biochemical Mechanistic Pathway of Cell Death Induced by Metal-Based Chemotherapeutic Agents -- 7.1 Introduction -- 7.2 Mechanism of Action of Metallodrugs -- 7.2.1 Molecular Mechanism of Action of Metallodrugs by Targeting DNA and Non-DNA Intracellular Components -- 7.2.2 Cisplatin Resistance Mechanism -- 7.2.3 Mechanism of Action of Ruthenium Complexes -- 7.2.4 Molecular Mechanism of Action Based on Different "Activation" Pathways -- 7.2.4.1 Activation by Hydrolysis Pathway -- 7.2.4.2 Activation by Reductive Pathway -- 7.2.4.3 Activation under Hypoxic Conditions -- 7.3 Metal Complexes as Prodrugs for Bioreductive Activation -- 7.4 Apoptosis -- 7.4.1 Hallmarks of Apoptosis -- 7.4.1.1 Internucleosomal DNA Fragmentation -- 7.4.1.2 Caspase Activation -- 7.4.1.3 Bcl-2 Apoptotic Proteins -- 7.4.2 Factors that Trigger Apoptosis in Metallodrugs -- 7.5 Role of ROS and Glutathiones -- 7.5.1 Superoxide Dismutase (SOD) Enzyme -- 7.5.2 Anticancer Metal Complexes Activating ROS-Mediated Signaling from Mitochondria -- References. Chapter 8: Combination Drug Strategies for Targeting Specific Biochemical Pathways for Superior Therapeutic Potency -- 8.1 Historical Background -- 8.2 Targeted Therapies -- 8.3 CRISPR Gene-Editing Techniques -- 8.4 New Combination Treatment Strategies -- 8.5 Metal Complex-Based Combination Therapies -- 8.6 Metal Complex-Biomolecule Conjugation in Targeted Cancer Therapy -- 8.6.1 Folic Acid-Conjugated Metal Complexes -- 8.6.2 Albumin-Conjugated Metal Complexes -- 8.6.3 Biotin-Conjugated Metal Complexes -- 8.7 Future Prospects -- References -- Chapter 9: Advanced Drug Delivery Strategies for Metal-Based Anticancer Drugs -- 9.1 Introduction -- 9.2 Graphene Oxide (GO) in Drug Delivery -- 9.2.1 Optical Imaging and Theranostics -- 9.2.2 Targeted Drug Delivery -- 9.2.3 Controlled and Stimulated Responsive Drug Release pH-Responsive Graphene-Based DDSs -- 9.3 Chitosan in Drug Delivery -- 9.4 PEGylated Systems in Drug Delivery -- 9.4.1 Redox-Triggered Drug Release of Graphene -- 9.5 Role of Nanotechnology in 3d Metal-Based Cancer Therapy -- 9.5.1 Copper Oxide Nanoparticles -- 9.5.2 Nickel Nanoparticles -- 9.5.3 Zinc Oxide Nanoparticles -- 9.5.4 Iron Oxide Nanoparticles -- References -- Chapter 10: Endoplasmic Reticulum (ER)-Targeted Metal-Based Anticancer Chemotherapeutic Agents -- 10.1 Introduction -- 10.2 Endoplasmic Reticulum (ER) as a Promising Therapeutic Target -- 10.3 Metal Complexes for ER Stress Generation -- References -- Chapter 11: Progress and Future Projections in Metal-Based Polymeric Anticancer Compounds -- 11.1 Introduction -- 11.2 Metal-Based Polymeric Compounds -- 11.2.1 Metal-Based Synthetic Polymer Drug Conjugates -- 11.2.2 Metal-Based Natural Polymer Drug Conjugates -- 11.2.3 Metal-Based Coordination Polymers (CPs) -- 11.3 Metallodendrimers -- 11.4 Polymer Conjugate with Chitosan NPs -- References -- Chapter 12: Conclusions -- Glossary. |
| Record Nr. | UNINA-9910855392603321 |
|
Arjmand Farukh
|
||
| Singapore : , : Springer, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advances in anticancer agents in medicinal chemistry . Volume 2 / / edited by Michelle Prudhomme
| Advances in anticancer agents in medicinal chemistry . Volume 2 / / edited by Michelle Prudhomme |
| Pubbl/distr/stampa | Sharjah : , : Bentham Science Publishers, , [2013] |
| Descrizione fisica | 1 online resource (495 p.) |
| Disciplina |
616.99
616.994061 |
| Altri autori (Persone) | PrudhommeMichelle |
| Collana | Advances in anticancer agents in medicinal chemistry |
| Soggetto topico |
Antineoplastic agents
Pharmaceutical chemistry |
| Soggetto genere / forma | Electronic books. |
| ISBN | 1-60805-496-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Cover; Title; EUL; Contents; Foreword; Preface; List of Contributors; Chapter 01; Chapter 02; Chapter 03; Chapter 04; Chapter 05; Chapter 06; Chapter 07; Chapter 08; Chapter 09; Chapter 10; Index |
| Record Nr. | UNINA-9910463096803321 |
| Sharjah : , : Bentham Science Publishers, , [2013] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advances in anticancer agents in medicinal chemistry . Volume 2 / / edited by Michelle Prudhomme
| Advances in anticancer agents in medicinal chemistry . Volume 2 / / edited by Michelle Prudhomme |
| Pubbl/distr/stampa | Sharjah : , : Bentham Science Publishers, , [2013] |
| Descrizione fisica | 1 online resource (495 p.) |
| Disciplina |
616.99
616.994061 |
| Altri autori (Persone) | PrudhommeMichelle |
| Collana | Advances in anticancer agents in medicinal chemistry |
| Soggetto topico |
Antineoplastic agents
Pharmaceutical chemistry |
| ISBN | 1-60805-496-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Cover; Title; EUL; Contents; Foreword; Preface; List of Contributors; Chapter 01; Chapter 02; Chapter 03; Chapter 04; Chapter 05; Chapter 06; Chapter 07; Chapter 08; Chapter 09; Chapter 10; Index |
| Record Nr. | UNINA-9910787562603321 |
| Sharjah : , : Bentham Science Publishers, , [2013] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advances in anticancer agents in medicinal chemistry . Volume 2 / / edited by Michelle Prudhomme
| Advances in anticancer agents in medicinal chemistry . Volume 2 / / edited by Michelle Prudhomme |
| Pubbl/distr/stampa | Sharjah : , : Bentham Science Publishers, , [2013] |
| Descrizione fisica | 1 online resource (495 p.) |
| Disciplina |
616.99
616.994061 |
| Altri autori (Persone) | PrudhommeMichelle |
| Collana | Advances in anticancer agents in medicinal chemistry |
| Soggetto topico |
Antineoplastic agents
Pharmaceutical chemistry |
| ISBN | 1-60805-496-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Cover; Title; EUL; Contents; Foreword; Preface; List of Contributors; Chapter 01; Chapter 02; Chapter 03; Chapter 04; Chapter 05; Chapter 06; Chapter 07; Chapter 08; Chapter 09; Chapter 10; Index |
| Record Nr. | UNINA-9910822339303321 |
| Sharjah : , : Bentham Science Publishers, , [2013] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advances in cancer drug targets . Volume 3 / / Atta-ur-Rahman, editor ; contributors Alain J. P. Alix [and thirty seven others]
| Advances in cancer drug targets . Volume 3 / / Atta-ur-Rahman, editor ; contributors Alain J. P. Alix [and thirty seven others] |
| Pubbl/distr/stampa | Sharjah, United Arab Emirates : , : Bentham Science Publishers, , 2016 |
| Descrizione fisica | 1 online resource (278 p.) |
| Disciplina | 616.994061 |
| Collana | Advances in Cancer Drug Targets |
| Soggetto topico |
Cancer - Chemotherapy
Drug targeting Drug delivery systems |
| Soggetto genere / forma | Electronic books. |
| ISBN | 1-68108-233-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
CONTENTS; PREFACE ; List of Contributors ; Neutrophil Elastase as a Target in Lung Cancer: the State of the Art ; 1. INTRODUCTION: NEUTROPHIL ELASTASE/Α-1ANTITRYPSIN IMBALANCE AS A LINK BETWEEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND LUNG CANCER; 2. MULTIFACETED FUNCTIONS OF NEUTROPHIL ELASTASE IN LUNG CANCER; 3. ENDEGNENOUS NEUTROPHIL ELASTASE INHIBITORS; 3.1. Proteinaceous Inhibitors; 3.2. Natural Compounds; 3.2.1. Glycosaminoglycans; 3.2.2. Phenolics; 3.2.3. Triterpenoids ; 3.2.4. Fatty Acids and Peptide Derivatives; 4. DESIGN OF DUAL NEUTROPHIL ELASTASE / MMP INHIBITORS
DESIGN OF DUAL HNE-MMP INHIBITORSCONCLUDING REMARKS; ADDITIONAL MATERIAL; 1. Molecular Modeling and Molecular Graphics; 2. Ligand and Receptor Preparation; 3. Docking Protocol; CONFLICT OF INTEREST; DISCLOSURE; ACKNOWLEDGEMENTS; ABBREVIATIONS; REFERENCES; Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack ; INTRODUCTION; MATERIALS AND METHODS; Cell Culture; SiRNA Sequences; SiRNA Transfection; Flow Cytometry; Complement-mediated Cytotoxicity Assay (CDC); C3-binding Studies; Real-Time RT-PCR; Statistical Analysis RESULTSDesign of siRNAs Specific for CD46, CD55 and CD59; SiRNA-mediated Downregulation of mCRP Expression; siRNA-mediated Augmentation of Tumor Cell Complement Lysis and Opsonization; Time-course of siRNA-induced mCRP Inhibition; Stable Downregulation of CD59 Using an Hairpin siRNA Expression Vector; DISCUSSION; CONFLICT OF INTEREST; DISCLOSURE; ACKNOWLEDGEMENT; ABBREVIATIONS; REFERENCES; Points of Therapeutic Intervention along the Wnt Signaling Pathway in Hepatocellular Carcinoma ; INTRODUCTION; THE WNT SIGNALING PATHWAY; Overview of the Wnt Signaling; The Wnt/β-catenin Pathway Aberrant Activation of the Wnt/β-catenin Pathway in HCCTARGETING THE WNT/Β-CATENIN PATHWAY IN HCC; Targeting the Upstream Components; Endogenous Inhibitors of the Ligand/Receptor Complex; Targeting Wnt Ligands and FZD Receptors ; Targeting the Dishevelled Protein; Cellular Trafficking and Targets; Targeting the β-catenin Destruction Complex; Targeting the β-catenin/TCF Transcriptional Complex; Pitfalls in Targeting the Wnt/β-catenin Pathway; CONCLUSIONS AND PERSPECTIVES ; CONFLICT OF INTEREST; DISCLOSURE; ACKNOWLEDGMENT; ABBREVIATIONS; REFERENCES Collaboration of Epithelial Mesenchymal Transition and Cancer Stem Cells: Sinister Routes for Chemoresistant Recurrent Ovarian Cancer INTRODUCTION; PATHOLOGY OF OVARIAN CANCER; TRANSITION FROM EPITHELIAL TO MESENCHYMAL PHENOTYPE AND THE PROGRESSION OF CANCER ; EVIDENCE OF EMT IN OVARIAN CANCER; STEM CELLS IN NORMAL OVARIES AND OVARIAN CANCER; SPHERE FORMATION AND THE CANCER STEM CELL PHENOTYPE OF THE OVARY; ASSOCIATION OF EMT AND CSCS: A MERGER FOR POTENTIAL CHEMORESISTANCE IN OVARIAN CANCER Cisplatin Induced EMT Generates Ovarian Cancer Stem-Like Cells: A Study on the OVCA 433 Cell Line as an Experimental Model |
| Record Nr. | UNINA-9910511486903321 |
| Sharjah, United Arab Emirates : , : Bentham Science Publishers, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advances in cancer drug targets . Volume 3 / / Atta-ur-Rahman, editor ; contributors Alain J. P. Alix [and thirty seven others]
| Advances in cancer drug targets . Volume 3 / / Atta-ur-Rahman, editor ; contributors Alain J. P. Alix [and thirty seven others] |
| Pubbl/distr/stampa | Sharjah, United Arab Emirates : , : Bentham Science Publishers, , 2016 |
| Descrizione fisica | 1 online resource (278 p.) |
| Disciplina | 616.994061 |
| Collana | Advances in Cancer Drug Targets |
| Soggetto topico |
Cancer - Chemotherapy
Drug targeting Drug delivery systems |
| ISBN | 1-68108-233-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
CONTENTS; PREFACE ; List of Contributors ; Neutrophil Elastase as a Target in Lung Cancer: the State of the Art ; 1. INTRODUCTION: NEUTROPHIL ELASTASE/Α-1ANTITRYPSIN IMBALANCE AS A LINK BETWEEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND LUNG CANCER; 2. MULTIFACETED FUNCTIONS OF NEUTROPHIL ELASTASE IN LUNG CANCER; 3. ENDEGNENOUS NEUTROPHIL ELASTASE INHIBITORS; 3.1. Proteinaceous Inhibitors; 3.2. Natural Compounds; 3.2.1. Glycosaminoglycans; 3.2.2. Phenolics; 3.2.3. Triterpenoids ; 3.2.4. Fatty Acids and Peptide Derivatives; 4. DESIGN OF DUAL NEUTROPHIL ELASTASE / MMP INHIBITORS
DESIGN OF DUAL HNE-MMP INHIBITORSCONCLUDING REMARKS; ADDITIONAL MATERIAL; 1. Molecular Modeling and Molecular Graphics; 2. Ligand and Receptor Preparation; 3. Docking Protocol; CONFLICT OF INTEREST; DISCLOSURE; ACKNOWLEDGEMENTS; ABBREVIATIONS; REFERENCES; Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack ; INTRODUCTION; MATERIALS AND METHODS; Cell Culture; SiRNA Sequences; SiRNA Transfection; Flow Cytometry; Complement-mediated Cytotoxicity Assay (CDC); C3-binding Studies; Real-Time RT-PCR; Statistical Analysis RESULTSDesign of siRNAs Specific for CD46, CD55 and CD59; SiRNA-mediated Downregulation of mCRP Expression; siRNA-mediated Augmentation of Tumor Cell Complement Lysis and Opsonization; Time-course of siRNA-induced mCRP Inhibition; Stable Downregulation of CD59 Using an Hairpin siRNA Expression Vector; DISCUSSION; CONFLICT OF INTEREST; DISCLOSURE; ACKNOWLEDGEMENT; ABBREVIATIONS; REFERENCES; Points of Therapeutic Intervention along the Wnt Signaling Pathway in Hepatocellular Carcinoma ; INTRODUCTION; THE WNT SIGNALING PATHWAY; Overview of the Wnt Signaling; The Wnt/β-catenin Pathway Aberrant Activation of the Wnt/β-catenin Pathway in HCCTARGETING THE WNT/Β-CATENIN PATHWAY IN HCC; Targeting the Upstream Components; Endogenous Inhibitors of the Ligand/Receptor Complex; Targeting Wnt Ligands and FZD Receptors ; Targeting the Dishevelled Protein; Cellular Trafficking and Targets; Targeting the β-catenin Destruction Complex; Targeting the β-catenin/TCF Transcriptional Complex; Pitfalls in Targeting the Wnt/β-catenin Pathway; CONCLUSIONS AND PERSPECTIVES ; CONFLICT OF INTEREST; DISCLOSURE; ACKNOWLEDGMENT; ABBREVIATIONS; REFERENCES Collaboration of Epithelial Mesenchymal Transition and Cancer Stem Cells: Sinister Routes for Chemoresistant Recurrent Ovarian Cancer INTRODUCTION; PATHOLOGY OF OVARIAN CANCER; TRANSITION FROM EPITHELIAL TO MESENCHYMAL PHENOTYPE AND THE PROGRESSION OF CANCER ; EVIDENCE OF EMT IN OVARIAN CANCER; STEM CELLS IN NORMAL OVARIES AND OVARIAN CANCER; SPHERE FORMATION AND THE CANCER STEM CELL PHENOTYPE OF THE OVARY; ASSOCIATION OF EMT AND CSCS: A MERGER FOR POTENTIAL CHEMORESISTANCE IN OVARIAN CANCER Cisplatin Induced EMT Generates Ovarian Cancer Stem-Like Cells: A Study on the OVCA 433 Cell Line as an Experimental Model |
| Record Nr. | UNINA-9910798274803321 |
| Sharjah, United Arab Emirates : , : Bentham Science Publishers, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advances in cancer drug targets . Volume 3 / / Atta-ur-Rahman, editor ; contributors Alain J. P. Alix [and thirty seven others]
| Advances in cancer drug targets . Volume 3 / / Atta-ur-Rahman, editor ; contributors Alain J. P. Alix [and thirty seven others] |
| Pubbl/distr/stampa | Sharjah, United Arab Emirates : , : Bentham Science Publishers, , 2016 |
| Descrizione fisica | 1 online resource (278 p.) |
| Disciplina | 616.994061 |
| Collana | Advances in Cancer Drug Targets |
| Soggetto topico |
Cancer - Chemotherapy
Drug targeting Drug delivery systems |
| ISBN | 1-68108-233-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
CONTENTS; PREFACE ; List of Contributors ; Neutrophil Elastase as a Target in Lung Cancer: the State of the Art ; 1. INTRODUCTION: NEUTROPHIL ELASTASE/Α-1ANTITRYPSIN IMBALANCE AS A LINK BETWEEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND LUNG CANCER; 2. MULTIFACETED FUNCTIONS OF NEUTROPHIL ELASTASE IN LUNG CANCER; 3. ENDEGNENOUS NEUTROPHIL ELASTASE INHIBITORS; 3.1. Proteinaceous Inhibitors; 3.2. Natural Compounds; 3.2.1. Glycosaminoglycans; 3.2.2. Phenolics; 3.2.3. Triterpenoids ; 3.2.4. Fatty Acids and Peptide Derivatives; 4. DESIGN OF DUAL NEUTROPHIL ELASTASE / MMP INHIBITORS
DESIGN OF DUAL HNE-MMP INHIBITORSCONCLUDING REMARKS; ADDITIONAL MATERIAL; 1. Molecular Modeling and Molecular Graphics; 2. Ligand and Receptor Preparation; 3. Docking Protocol; CONFLICT OF INTEREST; DISCLOSURE; ACKNOWLEDGEMENTS; ABBREVIATIONS; REFERENCES; Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack ; INTRODUCTION; MATERIALS AND METHODS; Cell Culture; SiRNA Sequences; SiRNA Transfection; Flow Cytometry; Complement-mediated Cytotoxicity Assay (CDC); C3-binding Studies; Real-Time RT-PCR; Statistical Analysis RESULTSDesign of siRNAs Specific for CD46, CD55 and CD59; SiRNA-mediated Downregulation of mCRP Expression; siRNA-mediated Augmentation of Tumor Cell Complement Lysis and Opsonization; Time-course of siRNA-induced mCRP Inhibition; Stable Downregulation of CD59 Using an Hairpin siRNA Expression Vector; DISCUSSION; CONFLICT OF INTEREST; DISCLOSURE; ACKNOWLEDGEMENT; ABBREVIATIONS; REFERENCES; Points of Therapeutic Intervention along the Wnt Signaling Pathway in Hepatocellular Carcinoma ; INTRODUCTION; THE WNT SIGNALING PATHWAY; Overview of the Wnt Signaling; The Wnt/β-catenin Pathway Aberrant Activation of the Wnt/β-catenin Pathway in HCCTARGETING THE WNT/Β-CATENIN PATHWAY IN HCC; Targeting the Upstream Components; Endogenous Inhibitors of the Ligand/Receptor Complex; Targeting Wnt Ligands and FZD Receptors ; Targeting the Dishevelled Protein; Cellular Trafficking and Targets; Targeting the β-catenin Destruction Complex; Targeting the β-catenin/TCF Transcriptional Complex; Pitfalls in Targeting the Wnt/β-catenin Pathway; CONCLUSIONS AND PERSPECTIVES ; CONFLICT OF INTEREST; DISCLOSURE; ACKNOWLEDGMENT; ABBREVIATIONS; REFERENCES Collaboration of Epithelial Mesenchymal Transition and Cancer Stem Cells: Sinister Routes for Chemoresistant Recurrent Ovarian Cancer INTRODUCTION; PATHOLOGY OF OVARIAN CANCER; TRANSITION FROM EPITHELIAL TO MESENCHYMAL PHENOTYPE AND THE PROGRESSION OF CANCER ; EVIDENCE OF EMT IN OVARIAN CANCER; STEM CELLS IN NORMAL OVARIES AND OVARIAN CANCER; SPHERE FORMATION AND THE CANCER STEM CELL PHENOTYPE OF THE OVARY; ASSOCIATION OF EMT AND CSCS: A MERGER FOR POTENTIAL CHEMORESISTANCE IN OVARIAN CANCER Cisplatin Induced EMT Generates Ovarian Cancer Stem-Like Cells: A Study on the OVCA 433 Cell Line as an Experimental Model |
| Record Nr. | UNINA-9910822427603321 |
| Sharjah, United Arab Emirates : , : Bentham Science Publishers, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Anti-angiogenesis drug discovery and development . Volume 4 / / edited by Atta-ur-Rahman & M. Iqbal Chaudhary
| Anti-angiogenesis drug discovery and development . Volume 4 / / edited by Atta-ur-Rahman & M. Iqbal Chaudhary |
| Pubbl/distr/stampa | Sharjah, U.A.E. : , : Bentham Books, , [2019] |
| Descrizione fisica | 1 online resource (242 pages) |
| Disciplina | 616.994061 |
| Soggetto topico | Neovascularization inhibitors |
| Soggetto genere / forma | Electronic books. |
| ISBN | 1-68108-397-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910511675703321 |
| Sharjah, U.A.E. : , : Bentham Books, , [2019] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Anti-angiogenesis drug discovery and development . Volume 4 / / edited by Atta-ur-Rahman & M. Iqbal Chaudhary
| Anti-angiogenesis drug discovery and development . Volume 4 / / edited by Atta-ur-Rahman & M. Iqbal Chaudhary |
| Pubbl/distr/stampa | Sharjah, U.A.E. : , : Bentham Books, , [2019] |
| Descrizione fisica | 1 online resource (242 pages) |
| Disciplina | 616.994061 |
| Soggetto topico | Neovascularization inhibitors |
| ISBN | 1-68108-397-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910796793403321 |
| Sharjah, U.A.E. : , : Bentham Books, , [2019] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
